These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 25918937)

  • 41. Mechanism of CDK activation revealed by the structure of a cyclinA-CDK2 complex.
    Jeffrey PD; Russo AA; Polyak K; Gibbs E; Hurwitz J; Massagué J; Pavletich NP
    Nature; 1995 Jul; 376(6538):313-20. PubMed ID: 7630397
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Biochemical characterization of Cdk2-Speedy/Ringo A2.
    Cheng A; Gerry S; Kaldis P; Solomon MJ
    BMC Biochem; 2005 Sep; 6():19. PubMed ID: 16191191
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Biochemical characterizations reveal different properties between CDK4/cyclin D1 and CDK2/cyclin A.
    Kim DM; Yang K; Yang BS
    Exp Mol Med; 2003 Oct; 35(5):421-30. PubMed ID: 14646596
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Design, synthesis and biological study of novel pyrido[2,3-d]pyrimidine as anti-proliferative CDK2 inhibitors.
    Ibrahim DA; Ismail NS
    Eur J Med Chem; 2011 Dec; 46(12):5825-32. PubMed ID: 22000924
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Cyclin-dependent kinase-2 as a target for cancer therapy: progress in the development of CDK2 inhibitors as anti-cancer agents.
    Chohan TA; Qian H; Pan Y; Chen JZ
    Curr Med Chem; 2015; 22(2):237-63. PubMed ID: 25386824
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Recent advances on structure-informed drug discovery of cyclin-dependent kinase-2 inhibitors.
    Duca JS
    Future Med Chem; 2009 Nov; 1(8):1453-66. PubMed ID: 21426059
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Study of a ligand complexed with Cdk2/Cdk4 by computer simulation.
    Jiang Y; Zou J; Gui C
    J Mol Model; 2005 Nov; 11(6):509-15. PubMed ID: 15928920
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cyclin E-cdk2 activation is associated with cell cycle arrest and inhibition of DNA replication induced by the thymidylate synthase inhibitor Tomudex.
    Yin MB; Guo B; Panadero A; Frank C; Wrzosek C; Slocum HK; Rustum YM
    Exp Cell Res; 1999 Feb; 247(1):189-99. PubMed ID: 10047461
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Extra precision docking, free energy calculation and molecular dynamics simulation studies of CDK2 inhibitors.
    Tripathi SK; Muttineni R; Singh SK
    J Theor Biol; 2013 Oct; 334():87-100. PubMed ID: 23727278
    [TBL] [Abstract][Full Text] [Related]  

  • 50. An in silico exploration of the interaction mechanism of pyrazolo[1,5-a]pyrimidine type CDK2 inhibitors.
    Li Y; Gao W; Li F; Wang J; Zhang J; Yang Y; Zhang S; Yang L
    Mol Biosyst; 2013 Sep; 9(9):2266-81. PubMed ID: 23864105
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Pyrazolo[3,4-c]pyridazines as novel and selective inhibitors of cyclin-dependent kinases.
    Braña MF; Cacho M; García ML; Mayoral EP; López B; de Pascual-Teresa B; Ramos A; Acero N; Llinares F; Muñoz-Mingarro D; Lozach O; Meijer L
    J Med Chem; 2005 Nov; 48(22):6843-54. PubMed ID: 16250643
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Structural and binding studies of cyclin-dependent kinase 2 with NU6140 inhibitor.
    Talapati SR; Goyal M; Nataraj V; Pothuganti M; R SM; Gore S; Ramachandra M; Antony T; More SS; Rao NK
    Chem Biol Drug Des; 2021 Nov; 98(5):857-868. PubMed ID: 34423559
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Briefly bound to activate: transient binding of a second catalytic magnesium activates the structure and dynamics of CDK2 kinase for catalysis.
    Bao ZQ; Jacobsen DM; Young MA
    Structure; 2011 May; 19(5):675-90. PubMed ID: 21565702
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Structural basis for the ORC1-Cyclin A association.
    Wang B; Song J
    Protein Sci; 2019 Sep; 28(9):1727-1733. PubMed ID: 31309634
    [TBL] [Abstract][Full Text] [Related]  

  • 55. p21 contains independent binding sites for cyclin and cdk2: both sites are required to inhibit cdk2 kinase activity.
    Fotedar R; Fitzgerald P; Rousselle T; Cannella D; Dorée M; Messier H; Fotedar A
    Oncogene; 1996 May; 12(10):2155-64. PubMed ID: 8668341
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Explicit treatment of active-site waters enhances quantum mechanical/implicit solvent scoring: Inhibition of CDK2 by new pyrazolo[1,5-a]pyrimidines.
    Hylsová M; Carbain B; Fanfrlík J; Musilová L; Haldar S; Köprülüoğlu C; Ajani H; Brahmkshatriya PS; Jorda R; Kryštof V; Hobza P; Echalier A; Paruch K; Lepšík M
    Eur J Med Chem; 2017 Jan; 126():1118-1128. PubMed ID: 28039837
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The structural basis for specificity of substrate and recruitment peptides for cyclin-dependent kinases.
    Brown NR; Noble ME; Endicott JA; Johnson LN
    Nat Cell Biol; 1999 Nov; 1(7):438-43. PubMed ID: 10559988
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Why are the truncated cyclin Es more effective CDK2 activators than the full-length isoforms?
    Rath SL; Senapati S
    Biochemistry; 2014 Jul; 53(28):4612-24. PubMed ID: 24947816
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The design of novel inhibitors for treating cancer by targeting CDC25B through disruption of CDC25B-CDK2/Cyclin A interaction using computational approaches.
    Li HL; Ma Y; Ma Y; Li Y; Chen XB; Dong WL; Wang RL
    Oncotarget; 2017 May; 8(20):33225-33240. PubMed ID: 28402259
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A model of the complex between cyclin-dependent kinase 5 and the activation domain of neuronal Cdk5 activator.
    Chou KC; Watenpaugh KD; Heinrikson RL
    Biochem Biophys Res Commun; 1999 Jun; 259(2):420-8. PubMed ID: 10362524
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.